현재 위치:홈 > 뉴스현황
04
20
2022
04
07
2022
03
14
2022
On March Bio Ray Lab's self-developed new-generation EP4 receptor small molecule antagonist YY001 clinical trial application was officially approved by the National Medical Products Administration (NMPA), agreeing to conduct Phase 1 clinical trials for advanced solid tumors.
03
14
2022
Shanghai Medicilon Inc. (Medicilon) was selected as a constituent stock of the "STAR 50" Index.
03
02
2022
Medicilon has overcome technical problems in R&D, delivered more than expected “answer sheets”, promoted the progress of projects efficiently, and increased collaboration efforts. Medicilon has won the trust and awards of clients with their strength and hard work.